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Abstract: During the last few decades many short-chain peptides have been isolated from the venom of 
different scorpion species. These toxins inhibit a variety of K+ channels by binding to and plugging the 
pore of the channels from the extracellular side thereby inhibiting ionic fluxes through the plasma 
membrane. The high affinity and selectivity of some toxins promote these peptides to become lead 
compounds for potential therapeutic use. 
Voltage-gated K+ channels can be classified into several families based on their gating properties and 
sequence homology. Members of a given family may have high sequence similarity, such as Kv1.1, 
Kv1.2 and Kv1.3 channels, therefore selective inhibitors of one specific channel are quite rare. The lack 
of selectivity of such peptides and the inhibition of more types of channels might lead to undesired side 
effects upon therapeutic application or may lead to incorrect conclusion regarding the role of a 
particular ion channel in a physiological or pathophysiological response either in vitro or in vivo.  
Margatoxin (MgTx) is often considered as a high affinity and selective inhibitor of the Kv1.3 channel. 
MgTx consists of 39 amino acids stabilized by 3 disulfide bridges isolated from the venom of the 
scorpion Centruroides margaritatus. This peptide is widely used in ion channel research, however, a 
comprehensive study of its selectivity with electrophysiological methods has not been published yet. 
Using the patch-clamp technique we conducted a comprehensive assessment of the selectivity of MgTx. 
Measurements were carried out on L929 cells expressing mKv1.1 channels, human peripheral 
lymphocytes expressing Kv1.3 channels and transiently transfected tsA201 cells with the following ion 
channels: hKv1.1, hKv1.2, hKv1.3, hKv1.4-IR, hKv1.5, hKv1.6, hKv1.7, rKv2.1, Shaker-IR, hERG, 
hKCa1.1, hKCa3.1 and hNav1.5. Margatoxin is indeed high affinity inhibitor of Kv1.3 channel (Kd = 11.7 
pM) but is not selective, since it inhibits the Kv1.2 channel with even higher affinity (Kd = 6.4 pM) and 
Kv1.1 in the nanomolar range (Kd = 4.2 nM).  
Based on our comprehensive data MgTX has to be considered a non-selective Kv1.3 inhibitor, and thus, 
experiments aiming at elucidating the significance of Kv1.3 in in vitro or in vivo physiological 
responses have to be carefully evaluated. 
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Margatoxin (MgTx), an alpha-KTx scorpion toxin, is considered a selective inhibitor of the Kv1.3 K+ 47 
channel. This peptide is widely used in ion channel research; however, a comprehensive study of its 48 
selectivity with electrophysiological methods has not been published yet. The lack of selectivity might 49 
lead to undesired side effects upon therapeutic application or may lead to incorrect conclusion regarding 50 
the role of a particular ion channel in a physiological or pathophysiological response either in vitro or in 51 
vivo.  52 
Using the patch-clamp technique we characterized the selectivity profile of MgTx using L929 cells 53 
expressing mKv1.1 channels, human peripheral lymphocytes expressing Kv1.3 channels and transiently 54 
transfected tsA201 cells expressing hKv1.1, hKv1.2, hKv1.3, hKv1.4-IR, hKv1.5, hKv1.6, hKv1.7, rKv2.1, 55 
Shaker-IR, hERG, hKCa1.1, hKCa3.1 and hNav1.5 channels. MgTx is indeed a high affinity inhibitor of 56 
Kv1.3 (Kd = 11.7 pM) but is not selective, it inhibits the Kv1.2 channel with similar affinity (Kd = 6.4 pM) 57 
and Kv1.1 in the nanomolar range (Kd = 4.2 nM).  58 
Based on our comprehensive data MgTX has to be considered a non-selective Kv1.3 inhibitor, and thus, 59 
experiments aiming at elucidating the significance of Kv1.3 in in vitro or in vivo physiological responses 60 
have to be carefully evaluated. 61 
  62 
 63 
  64 
Keywords: Margatoxin, MgTx, non-selective, Kv1.3, Kv1.2  65 
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11. Introduction 66 
 67 
 Peptide toxins isolated from animal venoms are well known blockers of the pore of plasma 68 
membrane ion channels thereby inhibiting cellular functions including action potential generation, 69 
proliferation and differentiation (Jimenez-Vargas et al., 2012; Pedraza Escalona and Possani, 2013; 70 
Rodriguez de la Vega and Possani, 2004, 2005). This property may allow the therapeutic application of 71 
such molecules in various diseases such as asthma, cardiac arrhythmia, hypertension and T-cell mediated 72 
autoimmune diseases (Bergeron and Bingham, 2012; Chandy et al., 2004; Jimenez-Vargas et al., 2012; 73 
Panyi et al., 2006) or obesity and insulin resistance (Upadhyay et al., 2013).  74 
 K+ channels play a key role in the regulation of the membrane potential of excitable and non-75 
excitable cells (Abbott, 2006; Korn and Trapani, 2005; Varga et al., 2010; Varga et al., 2011). Kv1.3 is a 76 
voltage-gated K+ channel, which is expressed in a variety of cells and tissues  e.g. in the central nervous 77 
system, pancreatic islets, lymphocytes, etc. (Gutman et al., 2005). Interestingly, Kv1.3 is the dominant 78 
voltage-gated K+ channel of human T-lymphocytes and its expression is sensitively regulated during 79 
terminal differentiation of these cells (Wulff et al., 2003). For example, effector memory T cells (TEM) 80 
generated by repeated chronic antigen stimuli express a high number of Kv1.3 as compared to other K+ 81 
channels and their proliferation becomes exclusively sensitive to Kv1.3 inhibitors (Wulff et al., 2003). As 82 
TEM cells are responsible for the tissue damage in chronic autoimmune diseases, such as Multiple 83 
Sclerosis and Rheumatoid Arthritis, the therapeutic application of Kv1.3 blockers for the inhibition of TEM 84 
proliferation is imminent and well-supported in animal models of these diseases (Chi et al., 2012; Panyi 85 
et al., 2006).  86 
 Kv1.x channels share high sequence homology and tend to form functional heterotetrameric 87 
structures in different tissues. Kv1.2 is one of the channels having the highest similarity to Kv1.3. Kv1.2 is 88 
                                                          
1
 Non-standard abbreviations: rMgTx: recombinant margatoxin (Alomone Labs, Jerusalem, Israel, cat. No.: RTM-
325, Lot: MA103); sMgTx: synthetic margatoxin (Peptide Institute Inc. Osaka, Japan, cat. No.: 4290-s, Lot: 560914) 
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primarily expressed in the central and peripheral nervous system forming homotetramers or associated 89 
with other Kv1.x channel subunits (Coleman et al., 1999; Dodson et al., 2003). Several natural peptide 90 
toxins show high affinity to Kv1.3 but also block Kv1.2 channels e.g. Css20, Anuroctoxin, Noxiustoxin and 91 
Charybdotoxin (Bagdany et al., 2005; Corzo et al., 2008; Grissmer et al., 1994). Highly selective blockers 92 
of Kv1.3 are rarely isolated directly from animal venoms (but see Vm24 (Varga et al., 2012)), however, 93 
with site-directed mutations selective peptides can be constructed, as was demonstrated for ShK-170 94 
(Pennington et al., 2009),  Mokatoxin-1 (Takacs et al., 2009) and OSK1-20 (Mouhat et al., 2005).  95 
 Margatoxin (MgTx) is a 39 amino-acid-long peptide stabilized by 3 disulfide bridges with a 96 
molecular weight of 4185, isolated from the venom of the scorpion Centruroides margaritatus. (Garcia-97 
Calvo et al., 1993) This peptide is widely used in the field of ion channel research (Kalman et al., 1998; 98 
Koch et al., 1997). Margatoxin is considered as a high affinity and selective inhibitor of the Kv1.3 channel 99 
(Jang et al., 2011; Kazama et al., 2012; Toldi et al., 2013; Zhao et al., 2013) however, a comprehensive 100 
study of its selectivity with electrophysiological methods has not been published yet. When MgTx was 101 
isolated and its high affinity interaction with Kv1.3 was precisely characterized it was only tested on a 102 
limited number of channels excluding Kv1.1, Kv1.2 and Kv1.4 channels, those with high sequence 103 
homology to Kv1.3 (Garcia-Calvo et al., 1993). Later the authors who described MgTx and other 104 
workgroups refer to the peptide as potent blocker of Kv1.1, Kv1.2 and Kv1.3 channels (Anangi et al., 105 
2012; Koch et al., 1997; Suarez-Kurtz et al., 1999; Vianna-Jorge et al., 2003) whereas the references do 106 
not describe or contain any information about the interaction of MgTx and the Kv1.1 or Kv1.2 channels. 107 
In the absence of the selectivity profile of MgTx results from radioactively labeled MgTx binding assays or 108 
the biological effect of the peptide as a  direct proof of Kv1.3 expression is not fully straightforward 109 
(Arkett et al., 1994; Li et al., 2008; Saria et al., 1998). In addition, MgTx shares high sequence homology 110 
with other scorpion peptides that block both Kv1.3 and Kv1.2 channels with high affinity (Noxiustoxin, 111 
Css20) suggesting that MgTx may be a non-selective peptide as well. 112 
5 
 
We conducted electrophysiological measurements with the patch-clamp technique in voltage-113 
clamp mode to test the selectivity of MgTx. Measurements were carried out on L929 cells expressing 114 
mKv1.1 channels, human peripheral lymphocytes expressing Kv1.3 channels and tsA201 cells transiently 115 
transfected with the following ion channels: hKv1.1, hKv1.2, hKv1.3, hKv1.4-IR, hKv1.5, hKv1.6, hKv1.7, 116 
rKv2.1, Shaker-IR, hERG, hKCa1.1, hKCa3.1 and hNav1.5. Our results indicate that MgTx is not a highly 117 
selective inhibitor of Kv1.3 channels as had been assumed in several previous studies. 118 
 119 
2. Materials and methods 120 
 121 
2.1 Sequence alignments 122 
To obtain amino acid sequences of the toxins the NCBI protein database was used then for the alignment 123 
of the sequences the built-in blastp (protein-protein BLAST) algorithm was used. 124 
 125 
2.2 Chemicals 126 
Recombinant margatoxin (rMgTx) was purchased from Alomone Labs, (Jerusalem, Israel, cat. No.: RTM-127 
325, Lot: MA103). Synthetic margatoxin (sMgTx) was obtained from Peptide Institute Inc. (Osaka, Japan, 128 
cat. No.: 4290-s, Lot: 560914). Other chemicals were obtained from Sigma-Aldrich Kft, Budapest, 129 
Hungary. 130 
 131 
2.3 Cells 132 
tsA201 cells, derived from HEK-293 (Shen et al., 1995) were grown under standard conditions, as 133 
described previously (Corzo et al., 2008). Human peripheral lymphocytes were obtained from healthy 134 
volunteers. Mononuclear cells were isolated using Ficoll-Hypaque density gradient separation technique 135 
and cultured in 24-well culture plates in a 5% CO2 incubator at 37°C in RPMI 1640 medium supplemented 136 
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with 10% fetal calf serum (Sigma-Aldrich), 100 µg/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-137 
glutamine (density, 5 x 105 cells per ml) for 2 to 5 days. 5, 7.5 or 10 µg/ml phytohemagglutinin A (Sigma-138 
Aldrich) was added to the medium to increase K+ channel expression. L929 cells stably expressing mKv1.1 139 
channel have been described earlier (Grissmer et al., 1994) and were kind gifts from Dr. Heike Wulff 140 
(University of California, Davis, Davis, CA). 141 
 142 
2.4 Heterologous expression of ion channels 143 
tsA201 cells were transiently transfected with Ca2+ phosphate transfection kit (Sigma-Aldrich, Hungary) 144 
according to the manufacturer’s instructions with the following channel coding vectors: hKv1.1, hKv1.2, 145 
hKv1.6 and hKv1.7 pCMV6-GFP plasmid (OriGene Technologies, Rockville, MD). hKv1.3 (previously cloned 146 
into p-EGFP-C1 vector from pRc-CMV2 plasmid, kind gift from C. Deutsch, University of Pennsylvania, 147 
Philadelphia, PA ), hKv1.4-IR (inactivation ball deletion mutant) in pcDNA3 vector (kind gift from D.  148 
Fedida, University of British Columbia, Vancouver, Canada), hKv1.5 in pEYFP vector (kind gift from A. 149 
Felipe, University of Barcelona, Barcelona, Spain), rKv2.1 (gift from S. Korn, University of Connecticut, 150 
Storrs, CT), Shaker-IR (inactivation ball deletion mutant) (gift from G. Yellen, Harvard Medical School, 151 
Boston, MA), hKv11.1 (hERG, kind gift from SH. Heinemann, Max-Plank-Gesellschaft, Jena, Germany), 152 
KCa1.1 in pClneo vector (kind gift from T. Hoshi, University of Pennsylvania, Philadelphia, PA), hKCa3.1 in 153 
pEGFP-C1 vector (gift from H. Wulff, University of California, Davis CA) and hNav1.5 (gift from R. Horn, 154 
Thomas Jefferson University, Philadelphia, PA). hKv1.4-IR, rKv2.1, Shaker-IR, hERG, KCa3.1 and Nav1.5 155 
coding vectors were co-transfected with a plasmid coding green fluorescent protein (GFP) gene in a 156 
molar ratio of 10:1. Currents were recorded 24 or48 h after transfection. Positive transfectants were 157 
identified with Nikon TE2000U or TS100 fluorescence microscope (Nikon, Tokyo, Japan). The hKv1.2 158 
expression vector coding sequence (Origene RG222200) was confirmed by sequencing using the 159 
following primers: Forward1: AGCTCGTTTAGTGAACCGTCA, Reverse1: TGCTGTTGGAATAGGTGTGG, 160 
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Forward2:  TTTCGGGAAGATGAAGGCTA, Reverse2:  AGGAGGCCCAATTCTCTCAT, Forward3: 161 
TCCAGACACTCCAAAGGTC, Reverse3: CTCTCGTCGCTCTCCATCTC. 162 
 163 
2.5 Electrophysiology 164 
Measurements were carried out using patch-clamp technique in voltage-clamp mode. Whole cell 165 
currents were recorded on lymphocytes and L929 cells. Transfected tsA201 cells were studied in the 166 
outside-out configuration of patch-clamp. For the recordings Axon Axopatch 200A and 200B amplifiers 167 
and Axon Digidata 1200 and 1440 digitizers were used (Molecular Devices, Sunnyvale, CA). Micropipettes 168 
were pulled from GC 150 F-15 borosilicate capillaries (Harvard Apparatus Kent, UK) resulting in 3- to 5-169 
MΩ resistance in the bath solution. For most of the measurements the bath solution consisted of 145 170 
mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 5.5 mM glucose, 10 mM HEPES, pH 7.35. For the 171 
measurements of hKv11.1 (hERG) channels the extracellular solution contained 5 mM KCl, 10 mM HEPES, 172 
20 mM glucose, 2 mM CaCl2, 2 mM MgCl2, 0.1 mM CdCl2, 140 mM choline-chloride, pH 7.35. Bath 173 
solutions were supplemented with 0.1 mg/ml BSA when MgTx was dissolved in different concentrations. 174 
The measured osmolarity of the extracellular solutions was between 302 and 308 mOsM/L. Generally the 175 
pipette solution contained 140 mM KF, 2 mM MgCl2, 1 mM CaCl2, 10 mM HEPES and 11 mM EGTA, pH 176 
7.22. To measure Kv11.1 channels the intracellular solution consisted of 140 mM KCl, 10 mM HEPES, 177 
2mM MgCl2 and 10 mM EGTA, pH 7.22, for the KCa3.1 recordings it contained 150 mM K-aspartate, 5mM 178 
HEPES, 10 mM EGTA, 8.7 mM CaCl2, 2 mM MgCl2, pH 7.22 resulting in 1 µM free Ca
2+ in the solution to 179 
activate KCa3.1 channels fully (Grissmer et al., 1993). To measure KCa1.1 the intracellular solution 180 
contained 140 mM KCl, 10 mM EGTA, 9.69 mM CaCl2, 5 mM HEPES, pH 7.22 thus giving 5 µM free Ca
2+ 181 
concentration to allow the activation of KCa1.1 channels at moderate membrane depolarization 182 
(Avdonin et al., 2003).  The osmolarity of the pipette filling solutions was 295 mOsM/L.  183 
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To measure hKv1.1, hKv1.2, hKv1.3, hKv1.4, hKv1.5, hKv1.6, hKv1.7, Shaker and rKv2.1 currents 15 to 50 184 
ms long depolarization impulses were applied to +50 mV from a holding potential of -100 mV every 15 or 185 
30 s. For hKv11.1 channels, currents were evoked with a voltage step from a holding potential of -80 mV 186 
to +20 mV followed by a step to -40 mV, during the latter the peak current was measured. Pulses were 187 
delivered every 30 s. For KCa1.1 channels, a voltage step to +50 mV was preceded by a 10-ms 188 
hyperpolarization to -120 mV from a holding potential of 0 mV every 15 s. KCa3.1 currents were elicited 189 
every 15 s with voltage ramps to +50 mV from a holding potential of -100 mV. Nav1.5 currents were 190 
measured by applying depolarization pulses to 0 mV from a holding potential of -120 mV every 15s. 191 
To acquire and analyze the measured data pClamp9/10 software package was used. Current traces were 192 
lowpass-filtered by the analog four-pole Bessel filters of the amplifiers. The sampling frequency was 2-50 193 
kHz, at least twice the filter cut-off frequency. The effect of the toxins in a given concentration was 194 
determined as remaining current fraction (RF = I/I0, where I0 is the peak current in the absence of the 195 
toxin and I is the peak current at equilibrium block at a given toxin concentration). Points on the dose-196 
response curves represent the mean of 3-8 independent measurements where the error bars represent 197 
the S.E.M. Data points were fitted with a two-parameter Hill equation, RF = KdH/(KdH+[Tx]H), where Kd is 198 
the dissociation constant, H is the Hill coefficient and [Tx] is the toxin concentration. To estimate Kd from 199 
two toxin concentrations we used the Lineweaver-Burk analysis, where 1/RF was plotted as a function of 200 
toxin concentration and fitting a straight line to the points, where Kd = 1/slope.  201 
 202 
  203 
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3. Results 204 
 205 
3.1 Endogenous currents in tsA-201 cells 206 
Figure 1A shows that whole-cell clamped non-transfected tsa201 cells display an endogenous voltage-207 
gated outward current with an activation threshold of ~20 mV. The magnitude of this current was 208 
determined using depolarizing pulses to +50 mV from a holding potential of -100 mV (Fig. 1B). The mean 209 
current amplitude was 337.1 pA (N = 16, S.E.M. = 48.5 pA). Application of 1nM recombinant MgTx 210 
(rMgTx, Alomone Labs) in the extracellular solution did not inhibit the whole-cell endogenous current 211 
(RF=0.98, S.E.M.=0.01, Fig. 1C).  Figs. 1A and 1B also shows that the endogenous current significantly 212 
decreased upon excising a patch to outside-out configuration (11.6 pA, N = 9, S.E.M. = 0.8 pA). The box 213 
plots representing the distribution of the peak currents recorded in whole-cell and excised outside-out 214 
configuration are shown in Fig. 1D. Although the endogenous current is MgTx insensitive, measurements 215 
on transfected tsA201 cells were always carried out in outside-out patch configuration thereby 216 
decreasing the relevance of the endogenous current as background during recordings from 217 
heterologously expressed channels. 218 
 219 
3.2 Selectivity profile of MgTx 220 
Since high affinity toxins block K+ channels in the picomolar range, the effect of 1nM rMgTx on the 221 
different ion channels was tested to assess MgTx selectivity. Outside-out patch-clamp recordings of 222 
currents in the absence and presence of 1nM rMgTx are shown if Fig. 2A-N for hKv1.1 (A), hKv1.2 (B), 223 
hKv1.3 (C) hKv1.4 (D) hKv1.5 (E) hKv1.6 (F) hKv1.7 (G) rKv2.1 (H) hKv11.1 (I) Shaker IR (J) hKCa3.1 (K), 224 
hKCa1.1 (L) hNav1.5 (M) and mKv1.1 (N). Significant blocking effect of rMgTx was observed on both 225 
murine and human Kv1.1, as well as hKv1.2 and hKv1.3 channels (Fig. 2A, B, C, N). Despite the high 226 
sequence homology rMgTx had no significant effect on hKv1.4, hKv1.5, hKv1.6, hKv1.7 channels (Fig. 2D-227 
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G, nor on any of the additional channels tested in this study such as rKv2.1, Shaker, hKv11.1, hKCa3.1, 228 
hKCa1.1 and hNav1.5 channels (Fig. 2H-M). Remaining current fractions at 1 nM rMgTX concentration 229 
are summarized in Fig. 2O. 230 
The three ion channel types, which were inhibited by 1 nM rMgTX were further studied to obtain a more 231 
accurate rank order and potency of MgTx. Due to the low affinity block of hKv1.1 channels, a complete 232 
dose-response curve would have required very large quantities of rMgTx. Therefore we used the 233 
remaining current fractions at two measured concentrations to estimate the Kd values for mKv1.1 and 234 
hKv1.1 To this end we applied the Lineweaver-Burk analysis to obtain Kd values of 1.7 nM and 4.2 nM, 235 
respectively (Fig. 3A). The significantly higher affinity of rMgTx for hKv1.2 and hKv1.3 allowed the 236 
construction of a full dose-response relationship and the determination of the Kd values from the Hill 237 
equation. The protocols for obtaining the peak currents were identical to those in Fig. 2B and C, for 238 
hKv1.2 and hKv1.3, respectively. We found that rMgTx blocks hKv1.2 and hKv1.3 channels with Kd = 6.4 239 
pM and 11.7 pM respectively (Fig. 3B), the Hill coefficients were close to 1 in both cases. Fig. 3C shows 240 
that rMgTx blocks the hKv1.3 current quickly and reversibly, equilibrium block develops in ~ 1 min. 241 
following the start of the perfusion with toxin-containing solution (gray bar, 100 pM MgTx) and full 242 
recovery of the peak currents is in ~7 min. upon perfusing the recording chamber with toxin-free 243 
solution. On the contrary, the block of the hKv1.2 current (Fig. 3D) develops on a much slower time-244 
course and perfusion of the recording chamber with toxin-free medium results in very slow partial 245 
recovery from block. In the latter case cumulative dose-response relationships could not be obtained, 246 
thus, each point in the Fig. 3B was obtained from independent experiments for both hKv1.3 and hKv1.2 247 
for comparable results.   248 
For quality assurance of our data, we have performed two additional sets of experiments, both aiming at 249 
confirming the pharmacological activity of the rMgTx. First, the potency of rMgTx was confirmed in 250 
inhibiting the endogenous Kv1.3 channels expressed in activated human T lymphocytes. Fitting the dose-251 
11 
 
response relationship using the Hill equation resulted in Kd = 10.1 pM (Fig. 4A), in good agreement with 252 
previous data on the inhibition of endogenous or heterologously expressed Kv1.3 and our previously 253 
published results (Toth et al., 2009).  Second, we have characterized the inhibition of hKv1.2 and hKv1.3 254 
currents by MgTx obtained from a different source to rule out the possibility of peptide production error. 255 
Fig. 4B shows high affinity block of hKv1.2 and hKv1.3 by synthetic MgTx (sMgTx), Kd = 14.3 pM and Kd = 256 
12.0 pM were obtained, respectively. Thus sMgTx and rMgTx block hKv1.2 and hKv1.3 channels with 257 
similar affinities. High affinity block of Kv1.3 channels by sMgTx was also observed in activated 258 
lymphocytes (Kd = 22.8 pM, data not shown).  259 
 260 
  261 
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4. Discussion 262 
 263 
We aimed to screen the effect of MgTx on several different ion channels using the same methods and 264 
expression system for a reliable comparison of the results. We therefore chose the easy to perform 265 
transient expression technique in the widely used tsA201 cell line. First, we tested the tsA201 cells for 266 
the presence of endogenous currents as these currents may interfere with the interpretation of 267 
pharmacological experiments designed to characterize the heterologously expressed channels. As 268 
reported earlier HEK-293 cells express various ion channels endogenously (He and Soderlund, 2010; Jiang 269 
et al., 2002; Varghese et al., 2006; Yu and Kerchner, 1998; Zhu et al., 1998). Similarly, we recorded 270 
whole-cell outward currents evoked by depolarizing pulses in tsA201 cells, however, the current 271 
measured on outside-out patches was negligible.  Although the endogenous current was insensitive to 1 272 
nM rMgTx (Fig. 1C) and the overexpression of the channels may eliminate the contribution of the 273 
endogenous background current to the whole cell current, we chose overexpression and excised outside-274 
out patch-clamp (see Figs. 1A, B and D) to minimize the potential errors in the pharmacological data.   275 
Using such a recording configuration we tested the following ion channels: hKv1.1, hKv1.2, hKv1.3, 276 
hKv1.4-IR, hKv1.5, hKv1.6, hKv1.7, rKv2.1, Shaker-IR, hKv11.1 (hERG), hKCa1.1, hKCa3.1 and hNav1.5. We 277 
only found a significant blocking effect on hKv1.1, hKv1.2 and hKv1.3 channels. Our results show 278 
picomolar dissociation constants for hKv1.2 and hKv1.3 and nanomolar Kd for hKv1.1. An earlier study 279 
found rat Kv1.6 channels to be sensitive to MgTx (Kd = 5 nM) (Garcia-Calvo et al., 1993), however, we did 280 
not find a significant effect of 1 nM MgTx on human Kv1.6 channels (Fig. 2F). We confirmed these results 281 
on hKv1.2 and hKv1.3 channels using MgTx from an additional source. Synthetic MgTx blocked Kv1.2 and 282 
Kv1.3 channels expressed in tsA201 cells with values similar to those obtained with rMgTx confirming the 283 
comparable affinities for the two channels. 284 
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The inhibition of mKv1.1 current in stably transfected L929 cell line was slightly higher than that of 285 
human Kv1.1 measured in tsA201 cells. The difference in the Kd values may be due to the different 286 
expression systems and the different availability of possible interacting partners of the channel in tsA201 287 
and L929 cells or the difference in the primary structure of mKv1.1 and hKv1.1 channels (Coetzee et al., 288 
1999). The affinities of MgTx for hKv1.2 and hKv1.3 are quite similar; however, the kinetics of the block 289 
(Fig. 3C, D) suggests that the mode of association and dissociation of MgTx to the two receptors is 290 
different. Equilibrium block for Kv1.3 developed faster and this block was reversible upon perfusing the 291 
cells with toxin-free bath solution, whereas block kinetics for Kv1.2 were much slower and the blocking 292 
effect was only partially reversible or irreversible. We previously found similar blocking features for 293 
another peptide toxin, Css20, which has very high amino acid sequence identity with MgTx (76%) and has 294 
similar pharmacological properties as well. With docking simulations we identified the most likely 295 
interacting residue pairs between Css20 and the Kv1.2 and Kv1.3 channels. We propose that MgTx 296 
probably interacts mostly with the selectivity filter of Kv1.3 by plugging it with the K28 lysine residue and 297 
prefers contact with the turret and axially located residues of Kv1.2 via a hydrogen bonding network 298 
(Corzo et al., 2008). 299 
  300 
Blast analysis (Blastp algorithm, NCBI) of the amino acid sequence of MgTx shows the highest similarity 301 
to known, non-selective inhibitors of the Kv1.3 channel, such as Hongotoxin 1 (90%) (Koschak et al., 302 
1998), Noxiustoxin (79%) (Grissmer et al., 1994) and Css20 (76%) (Corzo et al., 2008) (Table 1.). These 303 
toxins inhibit both Kv1.2 and Kv1.3 channels with similar affinities. Known Kv1.3 selective toxins based on 304 
the definition of Giangiacomo (where at least a 100-fold difference between the Kd values of the toxin 305 
on a given channel is observed)(Giangiacomo et al., 2004), exhibit much lower sequence identity with 306 
MgTx such as OSK1 (61%) (Mouhat et al., 2005), Kaliotoxin (58%) (Grissmer et al., 1994) and Vm24 (45%) 307 
(Varga et al., 2012). 308 
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Based on solely the primary structure of the peptide and sequence homology with other peptides one 309 
cannot make accurate conclusions about the selectivity of a peptide toxin. However, the high similarity 310 
of the residues may suggest a similar 3D structure, and consequently the biological effect of the peptides 311 
may be also similar. Toxins in this group of similar peptides were isolated from different scorpion 312 
species, however, all belonging to the same genus Centruroides, indicating that the toxins have the same 313 
evolutional origin. Additionally, MgTx shows high sequence homology to other toxins isolated from other 314 
species belonging to the genus Centruroides (CllTx1 and CllTx2 from C. limpidus limpidus, Ce1, Ce2, Ce4 315 
and Ce5 from C. elegans), but the effect of these toxins on both Kv1.2 and Kv1.3 channels has not been 316 
determined yet. 317 
Well known, highly Kv1.3 selective toxins exhibit lower sequence identities with MgTx and are isolated 318 
from various scorpion genera. Based on this data it can be assumed that toxins of species of genus 319 
Centruroides possess common residues that allow the inhibition of more Kv1.x channels, therefore 320 
screening the effect of MgTx on especially Kv1.x channels can provide us valuable information about the 321 
residues that determine the receptor specificity of the peptide. 322 
In vivo studies of Kv1.3 blocker peptide toxins clearly show their potential in suppressing T-cell 323 
mediated inflammatory reactions (Tarcha et al., 2012; Varga et al., 2012). In such experiments selectivity 324 
of the toxin is crucial to avoid potential side effects by blocking other Kv1.X channels. Kv1.1 was shown 325 
to be expressed in neurons (Gutman et al., 2005; Sinha et al., 2006; Wang et al., 1994), differentiating 326 
chondrocytes (Varga et al., 2011) in the distal convoluted tubule in the kidney (San-Cristobal et al., 2013) 327 
in bone marrow-derived human mesenchymal stem cells (You et al., 2013). Importance of Kv1.1 328 
expression in the nervus vagus in cardiac function was shown in mice (Glasscock et al., 2010) and the 329 
channel is involved in the glucose-stimulated insulin release in β-cells (Ma et al., 2011). Kv1.2 is 330 
expressed in different neurons (Bakondi et al., 2008; Fulton et al., 2011; Rusznak et al., 2008; 331 
Utsunomiya et al., 2008; Wang et al., 1994) and the malfunction of both Kv1.1 and Kv1.2 channels were 332 
15 
 
shown to cause cerebellar ataxia (Browne et al., 1994; Xie et al., 2010). Consequently, the use of Kv1.3 333 
inhibitors with poor selectivity may alter the physiological functions mentioned above. For example, 334 
continuous, 8-day application of MgTx in vivo in minipigs caused hypersalivation and decrease of 335 
appetite (Koo et al., 1997). This effect may be due to the inhibition of Kv1.1 or Kv1.2 channels expressed 336 
in neurons involved in the regulation of salivation and the sensation of appetite. 337 
Our results show that MgTx inhibits hKv1.2 and hKv1.3 with high affinity in the picomolar range 338 
and both human and murine Kv1.1 in the nanomolar range, consequently if MgTx receptors are found on 339 
a given cell or tissue even with the confirmation of the presence of Kv1.3 in the plasma membrane with 340 
western blot, confocal microscopy etc., identification of other MgTx receptors such as Kv1.1 and Kv1.2 341 
channels may be missed. Therefore the use of MgTx in such experiments must be reconsidered. 342 
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Fig. 1, Bartok et al. 352 
 353 
 354 
Figure 1. Voltage-gated outward endogenous currents in  non-transfected tsA201 cells.  355 
Currents were evoked using a voltage ramp protocol (A) ranging from -120 mV to +50 mV in 200ms or 356 
using a 200-ms-long voltage step protocol to +50 mV (B) in either whole cell configuration  or following 357 
the excision of patches to outside out configuration (as indicated). The holding potential was 100 mV. 358 
(C) Whole-cell endogenous currents were evoked by 15-ms-long pulses to +50 mV from a holding 359 
potential of 100 mV before (control) and during the perfusion of the recording chamber with 1nM 360 
MgTx containing bath solution. 1 nM MgTx did not inhibit the whole-cell endogenous currents. (D) Box 361 
and whiskers plot of the endogenous currents in non-transfected tsa201 cells in whole cell and in excised 362 
outside out patch configuration. Peak currents were determined from current traces evoked as in panel 363 
B (N=17 and N=9 for whole-cell and outside-out configuration, respectively). Horizontal lines indicate the 364 
medians, the boxes indicate 25-75 percentile of the data whereas whiskers and dots indicate 10-90 365 
percentile and the outliers, respectively.  366 
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Legends to Fig 2  369 
Figure 2. Selectivity profile of MgTx.  370 
Effect of 1 nM MgTx was assayed on outside out patches excised from tsA201 cells transfected with 371 
different ion channel genes (A-M) and on L929 cells stably expressing mKv1.1 channels (N). 372 
Representative traces show the currents measured in the bath solution before the application of MgTx 373 
(control), after reaching equilibrium block upon application of 1 nM MgTx (1 nM MgTx) and after 374 
recovering from the block applying toxin free bath solution in the perfusion system (wash out). Traces 375 
were 3-point boxcar filtered. (A-H, J, N) currents were evoked from holding potentials of 100 mV by 376 
depolarizations to +50 mV for durations ranging from 15 ms to 50 ms as indicated on the panels. The 377 
time between depolarizing pulses was 15 s (panel labels go here with 15 ipi) or 30 s (panel labels go here 378 
with 15 ipi). hKv11.1 (I) currents were measured with a voltage step from a holding potential of -80 mV 379 
to +20 mV followed by a step to -40 mV, during the latter the peak current was measured. Pulses were 380 
delivered every 30 s. For hKCa1.1 (L) channels, a voltage step to +50 mV was preceded by a 10-ms 381 
hyperpolarization to -120 mV from a holding potential of 0 mV every 15 s. hKCa3.1 (K) currents were 382 
elicited every 15 s with voltage ramps to +50 mV from a holding potential of -120 mV. hNav1.5 (M) 383 
currents were measured by applying depolarization pulses to 0 mV from a holding potential of -120 mV 384 
every 15 s. (O) The effect of 100 pM and 1 nM MgTx on the peak currents was reported as the remaining 385 
current fraction (RF = I/I0, where I0 is the peak current in the absence of the toxin and I is the peak 386 
current at equilibrium block at a given toxin concentration). Bars represent the mean of 3-8 independent 387 
measurements, error bars indicate the S.E.M. MgTx blocked hKv1.1, mKv1.1, hKv1.2 and hKv1.3 channels 388 
at the applied concentrations. 389 
  390 
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Figure 3. Block of Kv1.1, Kv1.2 and Kv1.3 currents by MgTx.   395 
Peak currents were determined using protocols and experimental conditions as in Fig. 2. The effect of 396 
the toxins at a given concentration was determined as remaining current fraction (RF = I/I0, where I0 is 397 
the peak current in the absence of the toxin and I is the peak current at equilibrium block at a given toxin 398 
concentration) (A) Concentration dependence of the block of murine and human Kv1.1 channels by 399 
MgTx. Kd was determined from the Lineweaver-Burk analysis, where the reciprocal of the remaining 400 
current fraction (1/RF) is plotted as a function of toxin concentration and  fitting a line to the data points 401 
yields Kd = 1/slope assuming 1:1 channel-toxin stoichiometry. Kd = 1.72 nM for mKv1.1 and Kd = 4.18 nM 402 
Kv1.2
time (min)


































































































for hKv1.1 was obtained from the fits. (B) High affinity, concentration dependent block of Kv1.2 and 403 
Kv1.3 channels by MgTx. Points on the dose-response curves represent the mean of 3-8 independent 404 
measurements where the error bars represent the S.E.M. Data points were fitted with a two-parameter 405 
Hill equation, RF = KdH/(KdH+[Tx]H), where Kd is the dissociation constant, H is the Hill coefficient and [Tx] 406 
is the toxin concentration. The best fit yielded Kd = 6.35 pM, H = 0.95 for Kv1.2 and Kd = 11.73 pM, H = 407 
0.83 for Kv1.3. (C, D) Normalized peak currents measured in outside-out patch configuration on tsA201 408 
cells expressing Kv1.3 (C) or Kv1.2 (D) channels and plotted as a function of time as 100 pM MgTx was 409 
applied to the bath solution (gray bars) and then removed from the extracellular medium. Pulses were 410 
delivered every 15 s. Perfusion with toxin-free medium resulted in very slow partial recovery from block 411 
in case of Kv1.2 (D).  412 
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Figure 4. Reference measurements to confirm the pharmacological effects of MgTx 418 
(A)  Concentration dependence of the block of human T lymphocyte Kv1.3 channels by recombinant 419 
MgTx (rMgTx). Whole-cell Kv1.3 currents were recorded in human peripheral blood T cells using voltage 420 
protocols as for Fig 2 C.  Remaining current fraction was determined at various toxin concentrations as in 421 
described in the legends to Fig. 3. Points on the dose-response curves represent the mean of 3-5 422 
independent measurements where the error bars represent the S.E.M. Data points were fitted with a 423 
two-parameter Hill equation, RF = KdH/(KdH+[Tx]H), where Kd is the dissociation constant, H is the Hill 424 
coefficient and [Tx] is the toxin concentration. The best fit yielded Kd = 22.8 pM and H = 1.1. (B) 425 
Concentration dependence of the block of hKv1.2 and hKv1.3 channels by synthetic MgTx (sMgTx). 426 
Channels were expressed in tsa201 cells, outside-out patch currents were recorded using protocols and 427 
experimental conditions as for Fig 2 B (hKv1.2) and C (hKv1.3). The calculation of remaining current 428 
fraction and the construction of the dose-response curve were as in Fig 4A for n = 3-5 independent 429 
experiments at each toxin concentration.  The best fit yielded Kd = 14.3 pM, H = 0.94 for Kv1.2 and Kd = 430 
12 pM, H = 0.8 for Kv1.3. 431 
sMgTx concentration (pM)


























































Table 1 434 
 435 
 436 
Footnote to table 1: Sequence analysis (Blastp algorithm, NCBI) of MgTx. (A) Amino acid sequence of 437 
toxins with known affinities for Kv1.2 and Kv1.3 in decreasing identity % order. MgTx shows the highest 438 
similarity to known, non-selective inhibitors of Kv1.3 channel, such as Hongotoxin 1, Noxiustoxin and 439 
Css20. (B) Amino acid sequence of toxins wit high selectivity for Kv1.3 over Kv1.2.  Kv1.3 selective toxins 440 
OSK1, Kaliotoxin and Vm24 show much lower sequence identity with MgTx. In the tables we indicate the 441 
common name of the peptides, the scorpion species from those the peptides were isolated, and the full 442 
amino acid sequences of the peptides including the database accession numbers. The similarity is 443 
represented by the query cover, which gives the percent of the query length that is included in the 444 
aligned sequences and the maximum identity, the percent similarity between the query and subject 445 
sequences over the length of the coverage area. Kd (or IC50) values on Kv1.2 and Kv1.3 channels are 446 
shown in nM. For the values the following references were used: Hongotoxin1 (Koschak et al., 1998), 447 
Noxiustoxin (Grissmer et al., 1994), Css20 (Corzo et al., 2008), OSK1 (Mouhat et al., 2005), Kaliotoxin 448 
(Grissmer et al., 1994), Vm24 (Varga et al., 2012). The ratio of Kd values (Kd Kv1.2 / Kd Kv1.3) measures the 449 
selectivity of the peptides to Kv1.3 channel (Giangiacomo et al., 2004).  450 
   451 
MgTx Centruroides margaritatus TIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGKCKCYPH 100% 100% P40755.1
Hongotoxin 1 Centruroides limbatus TVIDVKCTSPKQCLPPCKAQFGIRAGAKCMNGKCKCYPH 100% 90% P59847.1 0.07 0.09 0.78
Noxiustoxin Centruroides noxius TIINVKCTSPKQCSKPCKELYGSSAGAKCMNGKCKCYNN 100% 79% P08815.3 2 1 2.00
Css20 Centruroides suffusus suffusus IFINVKCSSPQQCLKPCKAAFGISAGGKCINGKCKCYP- 97% 76% P85529.1 1.26 7.21 0.17








Kd Kv1.2 / Kd Kv1.3
MgTx Centruroides margaritatus -TIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGKCKCYPH 100% 100% P40755.1
OSK1 Orthochirus scrobiculosus GVIINVKCKISRQCLEPCK-KAGMRFG-KCMNGKCHCTPK 79% 61% P55896.1 5.4 0.014 385.71
Kaliotoxin Androctonus mauritanicus GVEINVKCSGSPQCLKPCK-DAGMRFG-KCMNRKCHCTP- 92% 58%AAB20997.1 >1000 0.65 >1538.46
Vm24 Vaejovis mexicanus smithi --AAAISCVGSPECPPKCR-AQGCKNG-KCMNRKCKCYYC 84% 45% P0DJ31.1 5-10 0.0029 >1724.14
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